Study summary

An EGFR-HER3 antibody-drug conjugate shrank tumors in nearly half of patients

Iza-bren early trials · 171 people, phase 1 and 2 · Published June 2026, Annals of Oncology

47.4%of tumors shrank

What was tested

Izalontamab brengitecan (iza-bren), a drug-carrying antibody aimed at both EGFR and HER3, in people whose cancer grew after EGFR pills. Pooled phase 1 and 2 data, no comparison group.

What they found

What it means

Now in a phase 3 trial against chemotherapy run by Bristol Myers Squibb.

Ann Oncol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.